Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

Jaipur: A study conducted by SMS Medical College has raised alarm bells as it reveals a significant rise in antibiotic resistance among Acinetobacter bacteria infections. The research, which analysed ...

In an effort to illustrate that genomic surveillance can build the foundation for scaleable precision phage therapy, an international collaboration analyzed the genomes of over 15,000 cases of ...

Hospital-acquired infections are often hard to treat because the corresponding pathogens become increasingly resistant against antibiotics. The bacterium Acinetobacter baumannii is particularly feared ...

Credit: Getty Images. A PDUFA target date of May 29, 2023 has been set for the application. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in ...

SHANGHAI and SAN FRANCISCO, May 18, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese ...

A new study from Emory University addresses the growing global crisis of antibiotic-resistant infections. Many of these drug-resistant bacteria are spread through hospitals, and there are few ...

FRANKFURT. Each year, over 670,000 people in Europe fall ill because of antibiotic-resistant pathogens, and 33,000 die from the infections. Especially feared are pathogens with resistances against ...